Here is a breakdown of major shareholders in AlloVir Inc (NASDAQ: ALVR)

AlloVir Inc (NASDAQ: ALVR) is -1.06% lower on its value in year-to-date trading and has touched a low of $0.62 and a high of $7.24 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ALVR stock was last observed hovering at around $0.67 in the last trading session, with the day’s loss setting it 0.0%.

Currently trading at $0.67, the stock is -2.78% and -45.54% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.07 million and changing 0.07% at the moment leaves the stock -73.89% off its SMA200. ALVR registered -89.49% loss for a year compared to 6-month loss of -77.35%. The firm has a 200-day simple moving average (SMA200) of $0.58.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -1.09% gain in the last 1 month and extending the period to 3 months gives it a -59.96%, and is -12.65% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.00% over the week and 6.13% over the month.

AlloVir Inc (ALVR) has around 106 employees, a market worth around $76.72M and $0.00M in sales. Distance from 52-week low is 7.94% and -90.71% from its 52-week high. The company has generated returns on investments over the last 12 months (-78.45%).

AlloVir Inc quarterly earnings per share for the current quarter are estimated at -$0.43.The EPS is expected to grow by 20.67% this year

130 institutions hold shares in AlloVir Inc (ALVR), with institutional investors hold 111.23% of the company’s shares. The shares outstanding are 93.09M, and float is at 56.98M with Short Float at 8.43%. Institutions hold 56.65% of the Float.

The top institutional shareholder in the company is FMR, LLC with over 9.52 million shares valued at $32.37 million. The investor’s holdings represent 8.35% of the ALVR Shares outstanding. As of Jun 29, 2023, the second largest holder is Wasatch Advisors LP with 6.64 million shares valued at $22.59 million to account for 5.83% of the shares outstanding. The other top investors are Artal Group S.A. which holds 6.6 million shares representing 5.79% and valued at over $22.43 million, while Alkeon Capital Management LLC holds 4.04% of the shares totaling 4.61 million with a market value of $15.66 million.

AlloVir Inc (ALVR) Insider Activity

A total of 10 insider transactions have happened at AlloVir Inc (ALVR) in the last six months, with sales accounting for 10 and purchases happening 0 times. The most recent transaction is an insider sale by Brainard Diana, the company’s Chief Executive Officer. SEC filings show that Brainard Diana sold 41,421 shares of the company’s common stock on Feb 05 at a price of $0.67 per share for a total of $27752.0. Following the sale, the insider now owns 0.82 million shares.

AlloVir Inc disclosed in a document filed with the SEC on Feb 05 that Sinha Vikas () sold a total of 18,331 shares of the company’s common stock. The trade occurred on Feb 05 and was made at $0.67 per share for $12282.0. Following the transaction, the insider now directly holds 1.15 million shares of the ALVR stock.

Still, SEC filings show that on Feb 05, Miller Edward (General Counsel) disposed off 8,869 shares at an average price of $0.67 for $5942.0. The insider now directly holds 225,363 shares of AlloVir Inc (ALVR).

AlloVir Inc (ALVR): Who are the competitors?

One of the company’s main competitors (and peers) include Merck & Co. Inc. (MRK) that is trading 16.62% up over the past 12 months.Roche Holding AG Akt (RO) lies in the list of competitors of the AlloVir Inc and is -28.04% lower over the same period from ALVRRogers Corp. (ROG) is -22.07% down on the 1-year trading charts.